Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 9Unknown 3Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Breast Neoplasms 20Lymphoma, Large B-Cell, Diffuse 16Lymphoma 14Neoplasms 13Sarcoma 10Hodgkin Disease 10Triple Negative Breast Neoplasms 9Lymphoma, Follicular 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Lymphoma, B-Cell 7Ovarian Neoplasms 6Burkitt Lymphoma 6Lymphoma, Non-Hodgkin 5Fallopian Tube Neoplasms 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Multiple Myeloma 4Sarcoma, Ewing 3Recurrence 3Leiomyosarcoma 3Inflammatory Breast Neoplasms 3Endometrial Neoplasms 3Carcinoma, Hepatocellular 3Urinary Bladder Neoplasms 2Sarcoma, Synovial 2Rhabdomyosarcoma 2Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Neurofibrosarcoma 2Neuroblastoma 2Lymphoproliferative Disorders 2Lymphoma, Mantle-Cell 2

Interventions

Dexamethasone 13Lenalidomide 11daratumumab 5carfilzomib 5Bortezomib 5Calcium Dobesilate 4Whole-Body Irradiation 3Tacrolimus 3Mycophenolic Acid 3Melphalan 3Cyclophosphamide 3ixazomib 2isatuximab 2fludarabine phosphate 2fludarabine 2belantamab mafodotin 2Etoposide 2venetoclax 1thymoglobulin 1selinexor 1pomalidomide 1poly ICLC 1citarinostat 1Transplantation 1Thalidomide 1Sirolimus 1Rituximab 1Positron Emission Tomography Computed Tomography 1Pharmaceutical Preparations 1Peripheral Blood Stem Cell Transplantation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Neoplasms, Plasma Cell × Doxorubicin × Clear all
NCT00871013 2026-05-11

Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy

University of Arkansas

Phase 2 Active not recruiting
160 enrolled
Plasma cell

Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡